معرفی
Anders Österborg is a Professor leading the research group 'Precision medicine in lymphoid malignancies including CLL; from new targets to real-world assessments' at the Department of Oncology-Pathology, Karolinska Institutet. His group's primary mission is to develop and optimize chemotherapy-free precision treatments for lymphoid malignancies, with a concentrated focus on Chronic Lymphocytic Leukemia (CLL) and B-cell lymphoma, aiming to enhance survival, prevent drug resistance, and minimize long-term toxicity.
Professor Österborg's research encompasses a broad spectrum within hematologic oncology, with core interests including:
- Precision Medicine: Developing targeted therapies tailored to specific molecular features of lymphoid cancers.
- Chronic Lymphocytic Leukemia (CLL): Investigating novel therapeutic strategies like BTK inhibitors (e.g., Ibrutinib, Zanubrutinib), BCL2 inhibitors (Venetoclax), and exploring mechanisms of resistance.
- B-cell Lymphoma: Researching pathogenesis and novel treatments, including targeting receptors like ROR1.
- Tumor Microenvironment: Understanding and targeting interactions between cancer cells and their surrounding stromal and immune cells (e.g., monocytes, CX3CR1 signaling).
- Immunotherapy: Exploring immune-based approaches, including vaccine strategies and immune modulation.
- Infections in Immunocompromised Hosts: A significant recent focus involves characterizing the immune response to SARS-CoV-2 infection and vaccination, particularly the long-term immunogenicity and impact of variants like Omicron, in patients with CLL and other immunocompromising conditions.
Analysis of Professor Österborg's recent publications reveals a strong emphasis on clinical and translational research. Key trends include evaluating the comparative effectiveness and long-term outcomes of novel targeted agents (especially BTK inhibitors like Zanubrutinib vs. Ibrutinib) in large clinical trials (ALPINE, SEQUOIA, GLOW) for both treatment-naive and relapsed/refractory CLL patients. Another major theme is the detailed investigation of immune dysfunction and responses to SARS-CoV-2 in immunocompromised individuals, particularly those with CLL undergoing targeted therapies, utilizing prospective clinical trials (COVAXID) and real-world data. Preclinical work focuses on identifying new therapeutic targets within the CLL microenvironment (e.g., leukotrienes, CX3CR1) and lymphoma cells (e.g., ROR1).
Professor Österborg actively mentors and advises PhD students within his research group, including Lisa Blixt, Wen Zhong, Agnes Mattsson, and Olina Lind. His group operates within the broader research environment of the Department of Oncology-Pathology at Karolinska Institutet, collaborating with a team of researchers, senior scientists (Docent), biomedical scientists, and other PhD students focused on lymphoid malignancies and immunotherapy.
